36 results on '"Ozaki, N."'
Search Results
2. Assessing the Real-World, Long-Term Impact of Lemborexant on Sleep Quality in a Home-Based Clinical Study
- Author
-
Miyata S, Iwamoto K, Okada I, Fujimoto A, Kogo Y, Mori D, Amano M, Matsuyama N, Nishida K, Ando M, Taoka T, Naganawa S, and Ozaki N
- Subjects
insomnia ,lemborexant ,objective sleep evaluation ,portable sleep eeg monitoring ,subjective sleep evaluation ,Psychiatry ,RC435-571 ,Neurophysiology and neuropsychology ,QP351-495 - Abstract
Seiko Miyata,1,* Kunihiro Iwamoto,1,* Ippei Okada,1,* Akihiro Fujimoto,2 Yuki Kogo,2 Daisuke Mori,1,3,4 Manabu Amano,5 Nao Matsuyama,5 Kazuki Nishida,5 Masahiko Ando,5 Toshiaki Taoka,6 Shinji Naganawa,7 Norio Ozaki1,4 1Department of Psychiatry, Nagoya University, Graduate School of Medicine, Nagoya, Japan; 2Medical Headquarters, Eisai Co., Ltd., Tokyo, Japan; 3Brain and Mind Research Center, Nagoya University, Nagoya, Japan; 4Pathophysiology of Mental Disorders, Nagoya University, Graduate School of Medicine, Nagoya, Japan; 5Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan; 6Department of Innovative Biomedical Visualization (Ibmv), Nagoya University, Graduate School of Medicine, Nagoya, Japan; 7Department of Radiology, Nagoya University, Graduate School of Medicine, Nagoya, Japan*These authors contributed equally to this workCorrespondence: Seiko Miyata, Department of Psychiatry, Nagoya University, Graduate School of Medicine, 65 Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan, Tel +81 52 744 2282, Fax +81 52 744 2293, Email miyata.seiko.v4@f.mail.nagoya-u.ac.jpPurpose: Both subjective and objective evaluations are essential for the treatment of insomnia. Lemborexant has been shown to be effective in the long-term based solely on a subjective basis, and no long-term objective measures have been evaluated under natural sleep conditions. Small, lightweight sleep electroencephalogram (EEG) monitor was used, instead of polysomnography, to objectively evaluate sleep at home 4 and 12 weeks after lemborexant treatment.Patients and Methods: Adults and elderly subjects with insomnia disorder, per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, were enrolled in this open-label, single-arm, single-center trial. Objective and subjective measures of sleep were prospectively assessed. Sleep disturbance, excessive sleepiness, and depressive symptoms were assessed using questionnaires.Results: A total of 45 subjects were screened, of which 33 were enrolled. Paired t-tests were conducted to evaluate changes in sleep variables and compared with the baseline; subjects showed significant improvements in objective sleep efficiency (SE) and subjective sleep parameters at weeks 4 and 12 following treatment with lemborexant. When baseline values were taken into account, a repeated-multivariate analysis of variance (MANOVA) revealed statistically significant changes in the objective measures. Sleep disturbance, excessive sleepiness, and depressive symptoms improved after three months of lemborexant treatment.Conclusion: Furthermore, lemborexant therapy improved nocturnal sleep, when measured objectively using sleep EEG monitoring at home, and improved daytime sleepiness and depressive symptoms in older adults with insomnia disorder.Keywords: insomnia, lemborexant, objective sleep evaluation, portable sleep EEG monitoring, subjective sleep evaluation
- Published
- 2024
3. Shock compression experiments using the DiPOLE 100-X laser on the high energy density instrument at the European x-ray free electron laser: Quantitative structural analysis of liquid Sn
- Author
-
Gorman, M. G., primary, McGonegle, D., additional, Smith, R. F., additional, Singh, S., additional, Jenkins, T., additional, McWilliams, R. S., additional, Albertazzi, B., additional, Ali, S. J., additional, Antonelli, L., additional, Armstrong, M. R., additional, Baehtz, C., additional, Ball, O. B., additional, Banerjee, S., additional, Belonoshko, A. B., additional, Benuzzi-Mounaix, A., additional, Bolme, C. A., additional, Bouffetier, V., additional, Briggs, R., additional, Buakor, K., additional, Butcher, T., additional, Di Dio Cafiso, S., additional, Cerantola, V., additional, Chantel, J., additional, Di Cicco, A., additional, Clarke, S., additional, Coleman, A. L., additional, Collier, J., additional, Collins, G. W., additional, Comley, A. J., additional, Coppari, F., additional, Cowan, T. E., additional, Cristoforetti, G., additional, Cynn, H., additional, Descamps, A., additional, Dorchies, F., additional, Duff, M. J., additional, Dwivedi, A., additional, Edwards, C., additional, Eggert, J. H., additional, Errandonea, D., additional, Fiquet, G., additional, Galtier, E., additional, Laso Garcia, A., additional, Ginestet, H., additional, Gizzi, L., additional, Gleason, A., additional, Goede, S., additional, Gonzalez, J. M., additional, Harmand, M., additional, Hartley, N. J., additional, Heighway, P. G., additional, Hernandez-Gomez, C., additional, Higginbotham, A., additional, Höppner, H., additional, Husband, R. J., additional, Hutchinson, T. M., additional, Hwang, H., additional, Lazicki, A. E., additional, Keen, D. A., additional, Kim, J., additional, Koester, P., additional, Konopkova, Z., additional, Kraus, D., additional, Krygier, A., additional, Labate, L., additional, Lee, Y., additional, Liermann, H.-P., additional, Mason, P., additional, Masruri, M., additional, Massani, B., additional, McBride, E. E., additional, McGuire, C., additional, McHardy, J. D., additional, Merkel, S., additional, Morard, G., additional, Nagler, B., additional, Nakatsutsumi, M., additional, Nguyen-Cong, K., additional, Norton, A.-M., additional, Oleynik, I. I., additional, Otzen, C., additional, Ozaki, N., additional, Pandolfi, S., additional, Peake, D. J., additional, Pelka, A., additional, Pereira, K. A., additional, Phillips, J. P., additional, Prescher, C., additional, Preston, T. R., additional, Randolph, L., additional, Ranjan, D., additional, Ravasio, A., additional, Redmer, R., additional, Rips, J., additional, Santamaria-Perez, D., additional, Savage, D. J., additional, Schoelmerich, M., additional, Schwinkendorf, J.-P., additional, Smith, J., additional, Sollier, A., additional, Spear, J., additional, Spindloe, C., additional, Stevenson, M., additional, Strohm, C., additional, Suer, T.-A., additional, Tang, M., additional, Toncian, M., additional, Toncian, T., additional, Tracy, S. J., additional, Trapananti, A., additional, Tschentscher, T., additional, Tyldesley, M., additional, Vennari, C. E., additional, Vinci, T., additional, Vogel, S. C., additional, Volz, T. J., additional, Vorberger, J., additional, Walsh, J. P. S., additional, Wark, J. S., additional, Willman, J. T., additional, Wollenweber, L., additional, Zastrau, U., additional, Brambrink, E., additional, Appel, K., additional, and McMahon, M. I., additional
- Published
- 2024
- Full Text
- View/download PDF
4. Advanced spectroscopic investigation of colour centres in LiF crystals irradiated with monochromatic hard x-rays
- Author
-
Vincenti, M A, primary, Montereali, R M, additional, Bonfigli, F, additional, Nichelatti, E, additional, Nigro, V, additional, Piccinini, M, additional, Koenig, M, additional, Mabey, P, additional, Rigon, G, additional, Dabrowski, H J, additional, Benkadoum, Y, additional, Mercere, P, additional, Da Silva, P, additional, Pikuz, T, additional, Ozaki, N, additional, Makarov, S, additional, Pikuz, S, additional, and Albertazzi, B, additional
- Published
- 2024
- Full Text
- View/download PDF
5. Shock-Induced Melting and Recrystallization of MoO3Studied by Dynamic X-Ray Diffraction
- Author
-
Kishimura, H., Kawai, N., Miyanishi, K., Sueda, K., Yabuuchi, T., Nakamura, H., Amouretti, A., Ozaki, N., Aimi, A., and Ichiyanagi, K.
- Abstract
Molybdenum(VI) oxide (MoO3) is a promising semiconductor material that can be used in several functional applications. Understanding the structural response of MoO3under high-pressure and high-temperature conditions is important for designing a material used in device applications. An X-ray free electron laser (XFEL) enables the structural response under extreme conditions to be probed at the nanosecond timescale. We describe laser-driven shock compression experiments on MoO3using an XFEL to directly observe the structural evolution of MoO3. When a laser-driven shock wave arrives at a pressure of 61 GPa, MoO3melts immediately and remains in the molten state for a few nanoseconds. Rapid recrystallization to the α-MoO3phase and a high-pressure phase MoO3-II is also observed on nanosecond timescales during pressure release. Our results provide insights into the kinetic and phase transition under shock compression and represent the advancement toward the understanding structural response of MoO3under high-pressure, high-temperature conditions, which has not been studied.
- Published
- 2024
- Full Text
- View/download PDF
6. Evaluation of learning curves for contact laser vaporization of the prostate using the 980 nm diode laser for benign prostatic hyperplasia.
- Author
-
Furumido J, Ozaki N, Matsugase Y, and Mori T
- Subjects
- Humans, Male, Aged, Retrospective Studies, Middle Aged, Aged, 80 and over, Operative Time, Prostate surgery, Prostate pathology, Treatment Outcome, Clinical Competence, Transurethral Resection of Prostate adverse effects, Transurethral Resection of Prostate methods, Prostatic Hyperplasia surgery, Learning Curve, Lasers, Semiconductor therapeutic use, Lasers, Semiconductor adverse effects, Laser Therapy adverse effects, Laser Therapy methods, Postoperative Complications etiology, Postoperative Complications epidemiology
- Abstract
Objectives: We investigated the background of patients who underwent contact laser vaporization of the prostate (CVP) surgery and the learning curve of the operators., Methods: A total of 207 patients who underwent CVP surgery for benign prostatic hyperplasia between August 2018 and March 2023 were included in this study. Patient background, perioperative results, pre- and postoperative urinary flow tests, and complications were collected retrospectively., Results: We enrolled 12 doctors who were divided into expert (five doctors) and novice (seven doctors) groups based on the number of TURP experiences before CVP. The median patient age was 73 years (51-92 years) and prostate volume was 56 cc (15-190 cc) with no difference between the expert and novice groups. Complications included urinary retention (eight cases), hematuria (four), urinary tract infection (four), intraoperative perforation (two), and postoperative stricture (one). Both cases of intraoperative perforation occurred in the novice group. The expert group had a significantly shorter operative time (38 vs. 66 min) and a higher operative efficacy of prostate volume divided by operative time (1.43 vs. 0.88 cc/min). Postoperatively, IPSS, quality of life scores, and postvoid residual urine volume decreased, and maximal flow rate increased; however, there was no significant difference between the groups. The expert group showed stable operative time and operative efficacy after about five to eight cases, while the novice group showed stable after about 15 cases., Conclusions: Our findings suggest that CVP was safely performed at our hospital, and operators with limited experience in TURP can achieve stable perioperative results., (© 2024 The Japanese Urological Association.)
- Published
- 2024
- Full Text
- View/download PDF
7. Biallelic null variants in PNPLA8 cause microcephaly by reducing the number of basal radial glia.
- Author
-
Nakamura Y, Shimada IS, Maroofian R, Falabella M, Zaki MS, Fujimoto M, Sato E, Takase H, Aoki S, Miyauchi A, Koshimizu E, Miyatake S, Arioka Y, Honda M, Higashi T, Miya F, Okubo Y, Ogawa I, Scardamaglia A, Miryounesi M, Alijanpour S, Ahmadabadi F, Herkenrath P, Dafsari HS, Velmans C, Al Balwi M, Vitobello A, Denommé-Pichon AS, Jeanne M, Civit A, Abdel-Hamid MS, Naderi H, Darvish H, Bakhtiari S, Kruer MC, Carroll CJ, Ghayoor Karimiani E, Khailany RA, Abdulqadir TA, Ozaslan M, Bauer P, Zifarelli G, Seifi T, Zamani M, Al Alam C, Alvi JR, Sultan T, Efthymiou S, Pope SAS, Haginoya K, Matsunaga T, Osaka H, Matsumoto N, Ozaki N, Ohkawa Y, Oki S, Tsunoda T, Pitceathly RDS, Taketomi Y, Houlden H, Murakami M, Kato Y, and Saitoh S
- Abstract
Patatin-like phospholipase domain-containing lipase 8 (PNPLA8), one of the calcium-independent phospholipase A2 enzymes, is involved in various physiological processes through the maintenance of membrane phospholipids. Biallelic variants in PNPLA8 have been associated with a range of paediatric neurodegenerative disorders. However, the phenotypic spectrum, genotype-phenotype correlations and the underlying mechanisms are poorly understood. Here, we newly identified 14 individuals from 12 unrelated families with biallelic ultra-rare variants in PNPLA8 presenting with a wide phenotypic spectrum of clinical features. Analysis of the clinical features of current and previously reported individuals (25 affected individuals across 20 families) showed that PNPLA8-related neurological diseases manifest as a continuum ranging from variable developmental and/or degenerative epileptic-dyskinetic encephalopathy to childhood-onset neurodegeneration. We found that complete loss of PNPLA8 was associated with the more profound end of the spectrum, with congenital microcephaly. Using cerebral organoids generated from human induced pluripotent stem cells, we found that loss of PNPLA8 led to developmental defects by reducing the number of basal radial glial cells and upper-layer neurons. Spatial transcriptomics revealed that loss of PNPLA8 altered the fate specification of apical radial glial cells, as reflected by the enrichment of gene sets related to the cell cycle, basal radial glial cells and neural differentiation. Neural progenitor cells lacking PNPLA8 showed a reduced amount of lysophosphatidic acid, lysophosphatidylethanolamine and phosphatidic acid. The reduced number of basal radial glial cells in patient-derived cerebral organoids was rescued, in part, by the addition of lysophosphatidic acid. Our data suggest that PNPLA8 is crucial to meet phospholipid synthetic needs and to produce abundant basal radial glial cells in human brain development., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain.)
- Published
- 2024
- Full Text
- View/download PDF
8. Gnao1 is a molecular switch that regulates the Rho signaling pathway in differentiating neurons.
- Author
-
Taira R, Akamine S, Okuzono S, Fujii F, Hatai E, Yonemoto K, Takemoto R, Kato H, Masuda K, Kato TA, Kira R, Tsujimura K, Yamamura K, Ozaki N, Ohga S, and Sakai Y
- Subjects
- Humans, Mice, Animals, rho-Associated Kinases metabolism, Organoids metabolism, Amides pharmacology, Pyridines, GTP-Binding Protein alpha Subunits, Gi-Go metabolism, GTP-Binding Protein alpha Subunits, Gi-Go genetics, Neurons metabolism, Signal Transduction, Induced Pluripotent Stem Cells metabolism, Induced Pluripotent Stem Cells cytology, rho GTP-Binding Proteins metabolism, rho GTP-Binding Proteins genetics, Cell Differentiation
- Abstract
GNAO1 encodes G protein subunit alpha O1 (Gαo). Pathogenic variations in GNAO1 cause developmental delay, intractable seizures, and progressive involuntary movements from early infancy. Because the functional role of GNAO1 in the developing brain remains unclear, therapeutic strategies are still unestablished for patients presenting with GNAO1-associated encephalopathy. We herein report that siRNA-mediated depletion of Gnao1 perturbs the expression of transcripts associated with Rho GTPase signaling in Neuro2a cells. Consistently, siRNA treatment hampered neurite outgrowth and extension. Growth cone formation was markedly disrupted in monolayer neurons differentiated from iPSCs from a patient with a pathogenic variant of Gαo (p.G203R). This variant disabled neuro-spherical assembly, acquisition of the organized structure, and polarized signals of phospho-MLC2 in cortical organoids from the patient's iPSCs. We confirmed that the Rho kinase inhibitor Y27632 restored these morphological phenotypes. Thus, Gαo determines the self-organizing process of the developing brain by regulating the Rho-associated pathway. These data suggest that Rho GTPase pathway might be an alternative target of therapy for patients with GNAO1-associated encephalopathy., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
9. Secondary carnitine deficiency during refeeding in severely malnourished patients with eating disorders: a retrospective cohort study.
- Author
-
Imaeda M, Tanaka S, Oya-Ito T, Uematsu M, Fujigaki H, Saito K, Ando M, and Ozaki N
- Abstract
Background: Secondary carnitine deficiency in patients with anorexia nervosa has been rarely reported. This study aimed to investigate the occurrence of carnitine deficiency in severely malnourished patients with eating disorders during refeeding and assess its potential adverse effects on treatment outcomes., Method: In a cohort study of 56 female inpatients with eating disorders at a single hospital from March 2010 to December 2020, we measured plasma free carnitine (FC) levels and compared to those of a healthy control group (n = 35). The patients were categorized into three groups based on FC levels: FC deficiency (FC< 20 µmol/L), FC pre-deficiency (20 µmol/L ≤ FC< 36 µmol/L), and FC normal (36 µmol/L ≤ FC)., Results: Upon admission, the patients had a median age of 26 years (interquartile range [IQR]: 21-35) and a median body mass index (BMI) of 13.8 kg/m
2 (IQR: 12.8-14.8). Carnitine deficiency or pre-deficiency was identified in 57% of the patients. Hypocarnitinemia was associated with a decline in hemoglobin levels during refeeding (odds ratio [OR]: 0.445; 95% confidence interval [CI]: 0.214-0.926, p = 0.03), BMI at admission (OR: 0.478; 95% CI: 0.217-0.874, p = 0.014), and moderate or greater hepatic impairment at admission (OR: 6.385; 95% CI: 1.170-40.833, p = 0.032)., Conclusions: Hypocarnitinemia, particularly in cases of severe undernutrition (BMI< 13 kg/m2 at admission) was observed in severely malnourished patients with eating disorders during refeeding, a critical metabolic transition phase. Moderate or severe hepatic impairment at admission was considered a potential indicator of hypocarnitinemia. Although hypocarnitinemia was not associated with any apparent adverse events other than anemia during refeeding, the possibility that carnitine deficiency may be a risk factor for more serious complications during sudden increases in energy requirements associated with changes in physical status cannot be denied. Further research on the clinical significance of hypocarnitinemia in severely malnourished patients with eating disorders is warranted., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
10. Cilostazol improves the prognosis after hepatectomy in rats with sinusoidal obstruction syndrome.
- Author
-
Sugita H, Nakanuma S, Munesue S, Ishikawa T, Tokoro T, Takei R, Okazaki M, Kato K, Takada S, Makino I, Ozaki N, Yamamoto Y, and Yagi S
- Subjects
- Animals, Male, Prognosis, Oxaliplatin adverse effects, Liver Neoplasms surgery, Liver Neoplasms secondary, Liver Neoplasms drug therapy, Survival Rate, Rats, Tetrazoles administration & dosage, Tetrazoles pharmacology, Colorectal Neoplasms pathology, Liver pathology, Rats, Sprague-Dawley, Hepatic Veno-Occlusive Disease prevention & control, Hepatic Veno-Occlusive Disease etiology, Hepatic Veno-Occlusive Disease pathology, Cilostazol pharmacology, Hepatectomy adverse effects, Phosphodiesterase 3 Inhibitors pharmacology, Phosphodiesterase 3 Inhibitors therapeutic use, Disease Models, Animal
- Abstract
Background and Aim: Safe radical hepatectomy is important for patients with colorectal liver metastases complicated by sinusoidal obstruction syndrome (SOS) after oxaliplatin-based chemotherapy. This study aimed to investigate the impact of preoperative administration of cilostazol (CZ), an oral selective phosphodiesterase III inhibitor, on hepatectomy in rat SOS model., Material and Methods: Rats were divided into NL (normal liver), SOS (monocrotaline [MCT]-treated), and SOS + CZ (MCT + CZ-treated) groups. MCT or CZ was administered orally, and a 30% partial hepatectomy was performed 48 h after MCT administration. Postoperative survival rates were evaluated (n = 9, for each). Other rats were sacrificed on postoperative days (POD) 1 and 3 and evaluated histologically, immunohistochemically, biochemically, and using transmission electron microscopy (TEM), focusing particularly on SOS findings, liver damage, and liver sinusoidal endothelial cell (LSEC) injury., Results: The cumulative 10-day postoperative survival rate was significantly higher in the SOS + CZ group than in the SOS group (88.9% vs 33.3%, P = 0.001). Total SOS scores were significantly lower in the SOS + CZ group than in the SOS group on both POD 1 and 3. Serum biochemistry and immunohistochemistry showed that CZ reduced liver damage after hepatectomy. TEM revealed that LSECs were significantly preserved morphologically in the SOS + CZ group than in the SOS group on POD 1 (86.1 ± 8.2% vs 63.8 ± 9.3%, P = 0.003)., Conclusion: Preoperative CZ administration reduced liver injury by protecting LSECs and improved the prognosis after hepatectomy in rats with SOS., (© 2024 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
11. 15-Hydroxyeicosatrienoic acid induces nasal congestion by changing vascular functions in mice.
- Author
-
Ozaki N, Sakamoto N, Horikami D, Tachibana Y, Nagata N, Kobayashi K, Arai YT, Sone M, Hirayama K, and Murata T
- Subjects
- Animals, Mice, Humans, Male, Nasal Mucosa metabolism, Nasal Mucosa drug effects, Nasal Mucosa blood supply, Hydroxyeicosatetraenoic Acids metabolism, Female, Nasal Obstruction metabolism, Capillary Permeability drug effects, Ovalbumin, Vasodilation drug effects, Nasal Lavage Fluid, Rhinitis, Allergic metabolism, Disease Models, Animal
- Abstract
Background: Nasal congestion in allergic rhinitis (AR) is caused by vascular hyperpermeability and vascular relaxation of the nasal mucosa. We previously detected high levels of a lipoxygenation metabolite of dihomogammalinolenic acid, 15-hydroxy-8Z,11Z,13E-eicosatrienoic acid (15-HETrE) in the nasal lavage fluid of AR model mice. Here, we investigated the effects of 15-HETrE on vascular functions associated with nasal congestion., Methods: We measured 15-HETrE levels in the nasal lavage fluid of ovalbumin-induced AR model mice and nasal discharge of patients with AR. We also assessed nasal congestion and vascular relaxation in mice. Vascular contractility was investigated using isolated mouse aortas., Results: Five ovalbumin challenges increased 15-HETrE levels in AR model mice. 15-HETrE was also detected in patients who exhibiting AR-related symptoms. Intranasal administration of 15-HETrE elicited dyspnea-related behavior and decreased the nasal cavity volume in mice. Miles assay and whole-mount immunostaining revealed that 15-HETrE administration caused vascular hyperpermeability and relaxation of the nasal mucosa. Intravital imaging demonstrated that 15-HETrE relaxed the ear vessels that were precontracted via thromboxane receptor stimulation. Moreover, 15-HETrE dilated the isolated mouse aortas, and this effect was attenuated by K
+ channel inhibitors and prostaglandin D2 (DP) and prostacyclin (IP) receptor antagonists. Additionally, vasodilatory effects of 15-HETrE were accompanied by an increase in intracellular cAMP levels., Conclusions: Our results indicate that 15-HETrE, whose levels are elevated in the nasal cavity upon AR, can be a novel lipid mediator that exacerbates nasal congestion. Moreover, it can stimulate DP and IP receptors and downstream K+ channels to dilate the nasal mucosal vasculature., (Copyright © 2024 Japanese Society of Allergology. Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
12. Exploring the genetics of lithium response in bipolar disorders.
- Author
-
Herrera-Rivero M, Adli M, Akiyama K, Akula N, Amare AT, Ardau R, Arias B, Aubry JM, Backlund L, Bellivier F, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Birner A, Cearns M, Cervantes P, Chen HC, Chillotti C, Cichon S, Clark SR, Colom F, Cruceanu C, Czerski PM, Dalkner N, Degenhardt F, Del Zompo M, DePaulo JR, Etain B, Falkai P, Ferensztajn-Rochowiak E, Forstner AJ, Frank J, Frisén L, Frye MA, Fullerton JM, Gallo C, Gard S, Garnham JS, Goes FS, Grigoroiu-Serbanescu M, Grof P, Hashimoto R, Hasler R, Hauser J, Heilbronner U, Herms S, Hoffmann P, Hou L, Hsu YH, Jamain S, Jiménez E, Kahn JP, Kassem L, Kato T, Kelsoe J, Kittel-Schneider S, Kuo PH, Kusumi I, König B, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, Maj M, Manchia M, Marie-Claire C, Martinsson L, McCarthy MJ, McElroy SL, Millischer V, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Novák T, Nöthen MM, O'Donovan C, Ozaki N, Papiol S, Pfennig A, Pisanu C, Potash JB, Reif A, Reininghaus E, Richard-Lepouriel H, Roberts G, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schubert KO, Schulte EC, Schweizer BW, Severino G, Shekhtman T, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Squassina A, Stamm T, Stopkova P, Streit F, Tekola-Ayele F, Thalamuthu A, Tortorella A, Turecki G, Veeh J, Vieta E, Viswanath B, Witt SH, Zandi PP, Alda M, Bauer M, McMahon FJ, Mitchell PB, Rietschel M, Schulze TG, and Baune BT
- Abstract
Background: Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP. It also has been shown to have beneficial effects on disease-associated conditions, including sleep and cardiovascular disorders. However, the individual responses to Li treatment vary within and between diagnostic subtypes of BP (e.g. BP-I and BP-II) according to the clinical presentation. Moreover, long-term Li treatment has been linked to adverse side-effects that are a cause of concern and non-adherence, including the risk of developing chronic medical conditions such as thyroid and renal disease. In recent years, studies by the Consortium on Lithium Genetics (ConLiGen) have uncovered a number of genetic factors that contribute to the variability in Li treatment response in patients with BP. Here, we leveraged the ConLiGen cohort (N = 2064) to investigate the genetic basis of Li effects in BP. For this, we studied how Li response and linked genes associate with the psychiatric symptoms and polygenic load for medical comorbidities, placing particular emphasis on identifying differences between BP-I and BP-II., Results: We found that clinical response to Li treatment, measured with the Alda scale, was associated with a diminished burden of mania, depression, substance and alcohol abuse, psychosis and suicidal ideation in patients with BP-I and, in patients with BP-II, of depression only. Our genetic analyses showed that a stronger clinical response to Li was modestly related to lower polygenic load for diabetes and hypertension in BP-I but not BP-II. Moreover, our results suggested that a number of genes that have been previously linked to Li response variability in BP differentially relate to the psychiatric symptomatology, particularly to the numbers of manic and depressive episodes, and to the polygenic load for comorbid conditions, including diabetes, hypertension and hypothyroidism., Conclusions: Taken together, our findings suggest that the effects of Li on symptomatology and comorbidity in BP are partially modulated by common genetic factors, with differential effects between BP-I and BP-II., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
13. Analysis of human neuronal cells carrying ASTN2 deletion associated with psychiatric disorders.
- Author
-
Hayashi Y, Okumura H, Arioka Y, Kushima I, Mori D, Lo T, Otgonbayar G, Kato H, Nawa Y, Kimura H, Aleksic B, and Ozaki N
- Subjects
- Humans, Cell Differentiation genetics, DNA Copy Number Variations, Gene Deletion, Neural Stem Cells metabolism, Transcription Factors genetics, Induced Pluripotent Stem Cells metabolism, Mental Disorders genetics, Neurons metabolism, Glycoproteins genetics, Nerve Tissue Proteins genetics
- Abstract
Recent genetic studies have found common genomic risk variants among psychiatric disorders, strongly suggesting the overlaps in their molecular and cellular mechanism. Our research group identified the variant in ASTN2 as one of the candidate risk factors across these psychiatric disorders by whole-genome copy number variation analysis. However, the alterations in the human neuronal cells resulting from ASTN2 variants identified in patients remain unknown. To address this, we used patient-derived and genome-edited iPS cells with ASTN2 deletion; cells were further differentiated into neuronal cells. A comprehensive gene expression analysis using genome-edited iPS cells with variants on both alleles revealed that the expression level of ZNF558, a gene specifically expressed in human forebrain neural progenitor cells, was greatly reduced in ASTN2-deleted neuronal cells. Furthermore, the expression of the mitophagy-related gene SPATA18, which is repressed by ZNF558, and mitophagy activity were increased in ASTN2-deleted neuronal cells. These phenotypes were also detected in neuronal cells differentiated from patient-derived iPS cells with heterozygous ASTN2 deletion. Our results suggest that ASTN2 deletion is related to the common pathogenic mechanism of psychiatric disorders by regulating mitophagy via ZNF558., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
14. Guideline for evaluating the effects of psychotropic drugs on motor vehicle driving performance in Japan: A tiered approach for the assessment of clinically meaningful driving impairment.
- Author
-
Nakabayashi T, Iwamoto K, Yamaguchi A, Konishi Y, Saji M, Yoshimura R, Kanemoto K, Aoki H, Ando M, and Ozaki N
- Subjects
- Humans, Japan, Psychomotor Performance drug effects, Automobile Driving, Psychotropic Drugs adverse effects, Psychotropic Drugs administration & dosage, Psychotropic Drugs pharmacokinetics
- Abstract
In December 2022, the Ministry of Health, Labour and Welfare (MHLW) of Japan issued and implemented the guideline for evaluating the effects of psychotropic drugs on motor vehicle driving performance. This guideline recommends the use of a tiered approach to assess clinically meaningful driving impairment. It is noted that adverse events cannot be solely explained by pharmacokinetics, as the onset and duration of these events vary. Among these adverse events, those affecting alertness, such as drowsiness caused by psychotropic drugs on driving performance, are more frequently observed during initial treatment stages and dose escalation. Hence, when evaluating the effects of psychotropic drugs on driving performance, it becomes crucial to assess the persistence of clinically meaningful impairment. Therefore, the MHLW guideline, developed by the authors, emphasizes the need to assess the temporal profile of adverse events affecting driving in all clinical trials. Additionally, the guideline states that when conducting driving studies, the timing of multiple dosing should consider not only the pharmacokinetics of the investigational drug but also its tolerance., (© 2024 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.)
- Published
- 2024
- Full Text
- View/download PDF
15. Early identification of postpartum depression using machine learning.
- Author
-
Nakamura Y, Ueno T, Takahashi N, Ichikawa D, Yamauchi A, and Ozaki N
- Subjects
- Humans, Female, Adult, Early Diagnosis, Depression, Postpartum diagnosis, Machine Learning
- Published
- 2024
- Full Text
- View/download PDF
16. Mice with deficiency in Pcdh15, a gene associated with bipolar disorders, exhibit significantly elevated diurnal amplitudes of locomotion and body temperature.
- Author
-
Mori D, Inami C, Ikeda R, Sawahata M, Urata S, Yamaguchi ST, Kobayashi Y, Fujita K, Arioka Y, Okumura H, Kushima I, Kodama A, Suzuki T, Hirao T, Yoshimi A, Sobue A, Ito T, Noda Y, Mizoguchi H, Nagai T, Kaibuchi K, Okabe S, Nishiguchi K, Kume K, Yamada K, and Ozaki N
- Subjects
- Animals, Male, Mice, Behavior, Animal, Circadian Rhythm genetics, Circadian Rhythm physiology, Mice, Inbred C57BL, Prepulse Inhibition genetics, Proto-Oncogene Proteins c-fos metabolism, Proto-Oncogene Proteins c-fos genetics, Protocadherins, Bipolar Disorder genetics, Bipolar Disorder physiopathology, Body Temperature, Cadherins genetics, Disease Models, Animal, Locomotion genetics, Mice, Knockout
- Abstract
Genetic factors significantly affect the pathogenesis of psychiatric disorders. However, the specific pathogenic mechanisms underlying these effects are not fully understood. Recent extensive genomic studies have implicated the protocadherin-related 15 (PCDH15) gene in the onset of psychiatric disorders, such as bipolar disorder (BD). To further investigate the pathogenesis of these psychiatric disorders, we developed a mouse model lacking Pcdh15. Notably, although PCDH15 is primarily identified as the causative gene of Usher syndrome, which presents with visual and auditory impairments, our mice with Pcdh15 homozygous deletion (Pcdh15-null) did not exhibit observable structural abnormalities in either the retina or the inner ear. The Pcdh15-null mice showed very high levels of spontaneous motor activity which was too disturbed to perform standard behavioral testing. However, the Pcdh15 heterozygous deletion mice (Pcdh15-het) exhibited enhanced spontaneous locomotor activity, reduced prepulse inhibition, and diminished cliff avoidance behavior. These observations agreed with the symptoms observed in patients with various psychiatric disorders and several mouse models of psychiatric diseases. Specifically, the hyperactivity may mirror the manic episodes in BD. To obtain a more physiological, long-term quantification of the hyperactive phenotype, we implanted nano tag® sensor chips in the animals, to enable the continuous monitoring of both activity and body temperature. During the light-off period, Pcdh15-null exhibited elevated activity and body temperature compared with wild-type (WT) mice. However, we observed a decreased body temperature during the light-on period. Comprehensive brain activity was visualized using c-Fos mapping, which was assessed during the activity and temperature peak and trough. There was a stark contrast between the distribution of c-Fos expression in Pcdh15-null and WT brains during both the light-on and light-off periods. These results provide valuable insights into the neural basis of the behavioral and thermal characteristics of Pcdh15-deletion mice. Therefore, Pcdh15-deletion mice can be a novel model for BD with mania and other psychiatric disorders, with a strong genetic component that satisfies both construct and surface validity., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. Release dynamics of nanodiamonds created by laser-driven shock-compression of polyethylene terephthalate.
- Author
-
Heuser B, Bergermann A, Stevenson MG, Ranjan D, He Z, Lütgert J, Schumacher S, Bethkenhagen M, Descamps A, Galtier E, Gleason AE, Khaghani D, Glenn GD, Cunningham EF, Glenzer SH, Hartley NJ, Hernandez JA, Humphries OS, Katagiri K, Lee HJ, McBride EE, Miyanishi K, Nagler B, Ofori-Okai B, Ozaki N, Pandolfi S, Qu C, May PT, Redmer R, Schoenwaelder C, Sueda K, Yabuuchi T, Yabashi M, Lukic B, Rack A, Zinta LMV, Vinci T, Benuzzi-Mounaix A, Ravasio A, and Kraus D
- Abstract
Laser-driven dynamic compression experiments of plastic materials have found surprisingly fast formation of nanodiamonds (ND) via X-ray probing. This mechanism is relevant for planetary models, but could also open efficient synthesis routes for tailored NDs. We investigate the release mechanics of compressed NDs by molecular dynamics simulation of the isotropic expansion of finite size diamond from different P-T states. Analysing the structural integrity along different release paths via molecular dynamic simulations, we found substantial disintegration rates upon shock release, increasing with the on-Hugnoiot shock temperature. We also find that recrystallization can occur after the expansion and hence during the release, depending on subsequent cooling mechanisms. Our study suggests higher ND recovery rates from off-Hugoniot states, e.g., via double-shocks, due to faster cooling. Laser-driven shock compression experiments of polyethylene terephthalate (PET) samples with in situ X-ray probing at the simulated conditions found diamond signal that persists up to 11 ns after breakout. In the diffraction pattern, we observed peak shifts, which we attribute to thermal expansion of the NDs and thus a total release of pressure, which indicates the stability of the released NDs., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
18. Hepatic hemangioma in a simple liver cyst mimicking biliary cystic neoplasm.
- Author
-
Karashima R, Yamamura K, Oda E, Ozaki N, Ishiko T, Nagayama Y, Yamada R, Komohara Y, Koba I, and Beppu T
- Abstract
Background: Follow-up is recommended for an asymptomatic unilocular hepatic cystic lesion without wall-thickness and nodular components. A few liver cystic lesions represent biliary cystic neoplasms, which are difficult to differentiate from simple cysts with benign mural nodules on imaging alone., Case Presentation: An 84-year-old woman with a history of simple liver cyst diagnosed one year prior was admitted for evaluation of a developed mural nodule in the cystic lesion. She had no specific symptoms and no abnormalities in blood tests except for carcinoembryonic antigen (5.0 ng/mL) and carbohydrate antigen (43.5 U/mL) levels. Contrast-enhanced computed tomography revealed a well-defined, low-attenuation lesion without a septum that had enlarged from 41 to 47 mm. No dilation of the bile duct was observed. A gradually enhancing mural nodule, 14 mm in diameter, was confirmed. MRI revealed a uniform water-intense cystic lesion with a mural nodule. This was followed by T2-enhanced imaging showing peripheral hypointensity and central hyperintensity. Enhanced ultrasonography revealed an enhanced nodule with a distinct artery within it. A needle biopsy of the wall nodule or aspiration of intracystic fluid was not performed to avoid tumor cell spillage. The possibility of a neoplastic cystic tumor could not be ruled out, so a partial hepatectomy was performed with adequate margins. Pathologically, the cystic lesion contained a black 5 mm nodule consisting of a thin, whitish fibrous wall and dilated vessels lined by CD31 and CD34 positive endothelial cells. The final diagnosis was a rare cavernous hemangioma within a simple liver cyst., Conclusions: Cavernous hemangiomas mimicking well-enhanced mural nodules can arise from simple liver cysts. In less malignant cases, laparoscopic biopsy or percutaneous targeted biopsy of the mural nodules, together with needle ablation, may be recommended to avoid unnecessary surgery., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
19. Study of the genetic association between selected 3q29 region genes and schizophrenia and autism spectrum disorder in the Japanese population.
- Author
-
Otgonbayar G, Lo T, Hayashi Y, Furuta S, Aleksic B, Nawa Y, Kushima I, Kato H, Kimura H, and Ozaki N
- Subjects
- Humans, Female, Male, Japan, p21-Activated Kinases genetics, Chromosomes, Human, Pair 3 genetics, Adult, Mutation, Missense genetics, Case-Control Studies, Genetic Association Studies, East Asian People, Autism Spectrum Disorder genetics, Schizophrenia genetics, Asian People genetics, Genetic Predisposition to Disease genetics
- Abstract
Psychiatric disorders are highly inheritable, and most psychiatric disorders exhibit genetic overlap. Recent studies associated the 3q29 recurrent deletion with schizophrenia (SCZ) and autism spectrum disorder (ASD). In this study, we investigated the association of genes in the 3q29 region with SCZ and ASD. TM4SF19 and PAK2 were chosen as candidate genes for this study based on evidence from previous research. We sequenced TM4SF19 and PAK2 in 437 SCZ cases, 187 ASD cases and 524 controls in the Japanese population. Through targeted sequencing, we identified 6 missense variants among the cases (ASD & SCZ), 3 missense variants among controls, and 1 variant common to both cases and controls; however, no loss-of-function variants were identified. Fisher's exact test showed a significant association of variants in TM4SF19 among cases (p=0.0160). These results suggest TM4SF19 variants affect the etiology of SCZ and ASD in the Japanese population. Further research examining 3q29 region genes and their association with SCZ and ASD is thus needed.
- Published
- 2024
- Full Text
- View/download PDF
20. Duloxetine improves chronic orofacial pain and comorbid depressive symptoms in association with reduction of serotonin transporter protein through upregulation of ubiquitinated serotonin transporter protein.
- Author
-
Nakamura M, Yoshimi A, Tokura T, Kimura H, Kishi S, Miyauchi T, Iwamoto K, Ito M, Sato-Boku A, Mouri A, Nabeshima T, Ozaki N, and Noda Y
- Subjects
- Humans, Duloxetine Hydrochloride therapeutic use, Depression drug therapy, Serotonin, Up-Regulation, Facial Pain, Serotonin Plasma Membrane Transport Proteins metabolism, Chronic Pain complications, Chronic Pain drug therapy, Chronic Pain diagnosis
- Abstract
Abstract: Chronic orofacial pain (COP) is relieved by duloxetine (DLX) and frequently causes depressive symptoms. The aim of this study was to confirm effects of DLX on pain and depressive symptoms, and to associate with their effectiveness in platelet serotonin transporter (SERT) expression, which is a target molecule of DLX and plasma serotonin concentration in COP patients with depressive symptoms. We assessed for the severity of pain and depressive symptoms using the Visual Analog Scale (VAS) and 17-item Hamilton Depression Rating Scale (HDRS), respectively. Chronic orofacial pain patients were classified into 2 groups based on their HDRS before DLX-treatment: COP patients with (COP-D) and without (COP-ND) depressive symptoms. We found that the VAS and HDRS scores of both groups were significantly decreased after DLX treatment compared with those before DLX treatment. Upregulation of total SERT and downregulation of ubiquitinated SERT were observed before DLX treatment in both groups compared with healthy controls. After DLX treatment, there were no differences in total SERT of both groups and in ubiquitinated SERT of COP-D patients compared with healthy controls; whereas, ubiquitinated SERT of COP-ND patients remained downregulated. There were positive correlations between changes of serotonin concentrations and of VAS or HDRS scores in only COP-D patients. Our findings indicate that DLX improves not only pain but also comorbid depressive symptoms of COP-D patients. Duloxetine also reduces platelet SERT through upregulation of ubiquitinated SERT. As the result, decrease of plasma serotonin concentrations may be related to the efficacy of DLX in relieving pain and depression in COP patients., (Copyright © 2023 International Association for the Study of Pain.)
- Published
- 2024
- Full Text
- View/download PDF
21. Oxytocin-induced increases in cytokines and clinical effect on the core social features of autism: Analyses of RCT datasets.
- Author
-
Wakuda T, Benner S, Uemura Y, Nishimura T, Kojima M, Kuroda M, Matsumoto K, Kanai C, Inada N, Harada T, Kameno Y, Munesue T, Inoue J, Umemura K, Yamauchi A, Ogawa N, Kushima I, Suyama S, Saito T, Hamada J, Kano Y, Honda N, Kikuchi S, Seto M, Tomita H, Miyoshi N, Matsumoto M, Kawaguchi Y, Kanai K, Ikeda M, Nakamura I, Isomura S, Hirano Y, Onitsuka T, Ozaki N, Kosaka H, Okada T, Kuwabara H, and Yamasue H
- Subjects
- Adult, Male, Humans, Oxytocin, Cytokines, Interleukin-7, Interleukin-9 therapeutic use, Double-Blind Method, Administration, Intranasal, Randomized Controlled Trials as Topic, Autistic Disorder drug therapy, Autism Spectrum Disorder drug therapy
- Abstract
Although oxytocin may provide a novel therapeutics for the core features of autism spectrum disorder (ASD), previous results regarding the efficacy of repeated or higher dose oxytocin are controversial, and the underlying mechanisms remain unclear. The current study is aimed to clarify whether repeated oxytocin alter plasma cytokine levels in relation to clinical changes of autism social core feature. Here we analyzed cytokine concentrations using comprehensive proteomics of plasmas of 207 adult males with high-functioning ASD collected from two independent multi-center large-scale randomized controlled trials (RCTs): Testing effects of 4-week intranasal administrations of TTA-121 (A novel oxytocin spray with enhanced bioavailability: 3U, 6U, 10U, or 20U/day) and placebo in the crossover discovery RCT; 48U/day Syntocinon or placebo in the parallel-group verification RCT. Among the successfully quantified 17 cytokines, 4 weeks TTA-121 6U (the peak dose for clinical effects) significantly elevated IL-7 (9.74, 95 % confidence interval [CI] 3.59 to 15.90, False discovery rate corrected P (P
FDR ) < 0.001), IL-9 (56.64, 20.46 to 92.82, PFDR < 0.001) and MIP-1b (18.27, 4.96 to 31.57, PFDR < 0.001) compared with placebo. Inverted U-shape dose-response relationships peaking at TTA-121 6U were consistently observed for all these cytokines (IL-7: P < 0.001; IL-9: P < 0.001; MIP-1b: P = 0.002). Increased IL-7 and IL-9 in participants with ASD after 4 weeks TTA-121 6U administration compared with placebo was verified in the confirmatory analyses in the dataset before crossover (PFDR < 0.001). Furthermore, the changes in all these cytokines during 4 weeks of TTA-121 10U administration revealed associations with changes in reciprocity score, the original primary outcome, observed during the same period (IL-7: Coefficient = -0.05, -0.10 to 0.003, P = 0.067; IL-9: -0.01, -0.02 to -0.003, P = 0.005; MIP-1b: -0.02, -0.04 to -0.007, P = 0.005). These findings provide the first evidence for a role of interaction between oxytocin and neuroinflammation in the change of ASD core social features, and support the potential role of this interaction as a novel therapeutic seed. Trial registration: UMIN000015264, NCT03466671/UMIN000031412., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
22. Anxiety, depression and quality of life in patients with head and neck cancer undergoing laryngectomy: A long-term prospective evaluation.
- Author
-
Mukoyama N, Nishio N, Kimura H, Tokura T, Kishi S, Ogasawara K, Tsuzuki H, Yokoi S, Wada A, Shigeyama M, Ozaki N, Fujimoto Y, and Sone M
- Abstract
Background: This study aimed to assess anxiety, depression and quality of life (QoL) in patients with head and neck cancer undergoing laryngectomy using comprehensive self-reported questionnaires for a period of up to 5 years., Methods: This prospective observational study enrolled 150 consecutive patients with locally advanced head and neck cancer who underwent laryngectomy at Nagoya University Hospital between 2007 and 2020. Anxiety, depression and QoL were assessed at baseline (preoperative) and at 3, 6, 12, 24, 36, 48 and 60 months after surgery using two brief self-reported questionnaires, such as the eight-item Short Form Health Survey (SF-8) and the Hospital Anxiety and Depression Scale (HADS)., Results: The surgical procedures were total laryngectomy, pharyngo-laryngectomy and pharyngo-laryngo-oesophagectomy in 97 (65%), 41 (27%) and 12 (8%) patients, respectively. All eight items of the SF-8 were significantly worse than those of the normal population at baseline and at 3 months after surgery. However, general health, vitality, mental health and bodily pain improved to normal levels within 1 year after surgery and were maintained for 5 years. In this study, 35% of patients were categorised as potential cases of depression, and 35% were potential cases of anxiety. During the follow-up period, the proportion of patients with anxiety gradually decreased after surgery. Further analysis revealed that the SF-8 and HADS scores and trends in 89 patients without tumour recurrence were similar to those in the total enrolled 150 patients., Conclusion: Anxiety, depression and QoL in laryngectomised patients improved at 1 year after surgery and were maintained for up to 5 years., What This Paper Adds: What is already known on the subject Laryngectomy is associated with prolonged functional and psychological effects and has a major impact on patient quality of life (QoL). Several prospective studies evaluating the QoL in laryngectomised patients have been reported, in which significant deterioration in social functioning was found even 1 year after surgery. What this paper adds to existing knowledge One year is not a sufficient period for laryngectomised patients to return to normal life and spend their time in a social community. A recent review showed that most studies on QoL in laryngectomised patients were conducted under 1 year after the procedure, and there were not enough studies of sufficient quality. This is the first long-term prospective observational study of Japanese patients with head and neck cancer who underwent laryngectomy up to 5 years after surgery. What are the potential or actual clinical implications of this work? Our long-term observational study showed that the scores for anxiety, depression and QoL in laryngectomised patients improved at 1 year after surgery and were maintained for up to 5 years. Clinicians should recognize the importance of psychosocial risk factors in their QoL and multidisciplinary management, including social and psychological support, is essential for long-term laryngectomised survivors., (© 2024 Royal College of Speech and Language Therapists.)
- Published
- 2024
- Full Text
- View/download PDF
23. A rare incidence of a hepatic artery pseudoaneurysm following plastic biliary stent insertion.
- Author
-
Motohara T, Yamamura K, Ueno S, Takeno H, Nagayama Y, Oda E, Karashima R, Ozaki N, Masuda T, and Beppu T
- Subjects
- Male, Humans, Middle Aged, Hepatic Artery diagnostic imaging, Hepatic Artery pathology, Incidence, Stents adverse effects, Aneurysm, False diagnostic imaging, Aneurysm, False etiology, Aneurysm, False therapy, Hemobilia therapy, Hemobilia complications, Cholangitis complications
- Abstract
Hepatic artery pseudoaneurysms have been reported to occur in approximately 1% of cases after metal stenting for malignant biliary obstruction. In contrast, only a few cases have been reported as complications after plastic stenting for benign biliary disease. We report a 61-year-old man with cholangitis who presented with a rare complication of hemobilia after implantation of 7 Fr double pigtail plastic biliary stents. No bleeding was observed approximately one month after biliary stent tube removal. Contrast-enhanced CT scan revealed a circularly enhanced lesion (5 mm in diameter) in the arterial phase at the tip of the previously inserted plastic bile duct stent. Color Doppler ultrasonography enhanced the lesion and detected arterial blood flow inside. He was diagnosed with a hepatic artery pseudoaneurysm. However, he had no risk factors such as prolonged catheterization, severe cholangitis, liver abscess, or long-term steroid use. Superselective transarterial embolization using two metal microcoils was successfully completed without damage to the surrounding liver parenchyma. If hemobilia is suspected after insertion of a plastic bile duct stent, immediate monitoring using contrast-enhanced computed tomography or Doppler ultrasonography is recommended., (© 2024. Japanese Society of Gastroenterology.)
- Published
- 2024
- Full Text
- View/download PDF
24. Epac2 activation mediates glucagon-induced glucogenesis in primary rat hepatocytes.
- Author
-
Shiozaki-Takagi Y, Ozaki N, and Toyoda Y
- Subjects
- Rats, Animals, Guanine Nucleotide Exchange Factors genetics, Guanine Nucleotide Exchange Factors metabolism, RNA, Messenger metabolism, Glycogen metabolism, Glucagon metabolism, Hepatocytes metabolism, Benzene Derivatives, Sulfones
- Abstract
Aims/introduction: Glucagon plays an essential role in hepatic glucogenesis by enhancing glycogen breakdown, inducing gluconeogenesis, and suppressing glycogenesis. Moreover, glucagon increases cyclic adenosine monophosphate (cAMP) levels, thereby activating protein kinase A (PKA) and cAMP guanine nucleotide exchange factor (also known as Epac). Although the function of PKA in the liver has been studied extensively, the function of hepatic Epac is poorly understood. The aim of this study was to elucidate the role of Epac in mediating the action of glucagon on the hepatocytes., Materials and Methods: Epac mRNA and protein expression, localization, and activity in the hepatocytes were analyzed by reverse transcription polymerase chain reaction, western blotting, immunofluorescence staining, and Rap1 activity assay, respectively. Additionally, we investigated the effects of an Epac-specific activator, 8-CPT, and an Epac-specific inhibitor, ESI-05, on glycogen metabolism in isolated rat hepatocytes. Further mechanisms of glycogen metabolism were evaluated by examining glucokinase (GK) translocation and mRNA expression of gluconeogenic enzymes., Results: Epac2, but not Epac1, was predominantly expressed in the liver. Moreover, 8-CPT inhibited glycogen accumulation and GK translocation and enhanced the mRNA expression of gluconeogenic enzymes. ESI-05 failed to reverse glucagon-induced suppression of glycogen storage and partially inhibited glucagon-induced GK translocation and the mRNA expression of gluconeogenic enzymes., Conclusions: Epac signaling plays a role in mediating the glucogenic action of glucagon in the hepatocytes., (© 2024 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
25. A Case of Hereditary Coproporphyria in which the Patient's Course Improved after the Discontinuation of Givosiran.
- Author
-
Ozaki N, Hayashi Y, and Kiyota A
- Abstract
Hereditary coproporphyria (HCP) is caused by a partial deficiency of coproporphyrinogen oxidase during heme biosynthesis. Givosiran is approved for the treatment of acute hepatic porphyria. We herein report the case of a 47-year-old woman with HCP. Monthly givosiran administration improved her subjective symptoms and reduced her δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels to the normal range. However, givosiran was discontinued after six months due to a decreased renal function. The patient's ALA and PBG levels remained within the normal ranges, and her HCP-related symptoms resolved more than 2 years after the discontinuation of givosiran.
- Published
- 2024
- Full Text
- View/download PDF
26. Phenotypes for general behavior, activity, and body temperature in 3q29 deletion model mice.
- Author
-
Mori D, Ikeda R, Sawahata M, Yamaguchi S, Kodama A, Hirao T, Arioka Y, Okumura H, Inami C, Suzuki T, Hayashi Y, Kato H, Nawa Y, Miyata S, Kimura H, Kushima I, Aleksic B, Mizoguchi H, Nagai T, Nakazawa T, Hashimoto R, Kaibuchi K, Kume K, Yamada K, and Ozaki N
- Subjects
- Humans, Child, Mice, Animals, Chromosome Deletion, DNA Copy Number Variations, Body Temperature, Disease Models, Animal, Phenotype, Developmental Disabilities genetics, Intellectual Disability genetics
- Abstract
Whole genome analysis has identified rare copy number variations (CNV) that are strongly involved in the pathogenesis of psychiatric disorders, and 3q29 deletion has been found to have the largest effect size. The 3q29 deletion mice model (3q29-del mice) has been established as a good pathological model for schizophrenia based on phenotypic analysis; however, circadian rhythm and sleep, which are also closely related to neuropsychiatric disorders, have not been investigated. In this study, our aims were to reevaluate the pathogenesis of 3q29-del by recreating model mice and analyzing their behavior and to identify novel new insights into the temporal activity and temperature fluctuations of the mouse model using a recently developed small implantable accelerometer chip, Nano-tag. We generated 3q29-del mice using genome editing technology and reevaluated common behavioral phenotypes. We next implanted Nano-tag in the abdominal cavity of mice for continuous measurements of long-time activity and body temperature. Our model mice exhibited weight loss similar to that of other mice reported previously. A general behavioral battery test in the model mice revealed phenotypes similar to those observed in mouse models of schizophrenia, including increased rearing frequency. Intraperitoneal implantation of Nano-tag, a miniature acceleration sensor, resulted in hypersensitive and rapid increases in the activity and body temperature of 3q29-del mice upon switching to lights-off condition. Similar to the 3q29-del mice reported previously, these mice are a promising model animals for schizophrenia. Successive quantitative analysis may provide results that could help in treating sleep disorders closely associated with neuropsychiatric disorders., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
27. Machine learning algorithm-based estimation model for the severity of depression assessed using Montgomery-Asberg depression rating scale.
- Author
-
Shimamoto M, Ishizuka K, Ohtani K, Inada T, Yamamoto M, Tachibana M, Kimura H, Sakai Y, Kobayashi K, Ozaki N, and Ikeda M
- Subjects
- Humans, Reproducibility of Results, Depression
- Abstract
Aim: Depressive disorder is often evaluated using established rating scales. However, consistent data collection with these scales requires trained professionals. In the present study, the "rater & estimation-system" reliability was assessed between consensus evaluation by trained psychiatrists and the estimation by 2 models of the AI-MADRS (Montgomery-Asberg Depression Rating Scale) estimation system, a machine learning algorithm-based model developed to assess the severity of depression., Methods: During interviews with trained psychiatrists and the AI-MADRS estimation system, patients responded orally to machine-generated voice prompts from the AI-MADRS structured interview questions. The severity scores estimated from two models of the AI-MADRS estimation system, the max estimation model and the average estimation model, were compared with those by trained psychiatrists., Results: A total of 51 evaluation interviews conducted on 30 patients were analyzed. Pearson's correlation coefficient with the scores evaluated by trained psychiatrists was 0.76 (95% confidence interval 0.62-0.86) for the max estimation model, and 0.86 (0.76-0.92) for the average estimation model. The ANOVA ICC rater & estimation-system reliability with the evaluation scores by trained psychiatrists was 0.51 (-0.09 to 0.79) for the max estimation model, and 0.75 (0.55-0.86) for the average estimation model., Conclusion: The average estimation model of AI-MADRS demonstrated substantially acceptable rater & estimation-system reliability with trained psychiatrists. Accumulating a broader training dataset and the refinement of AI-MADRS interviews are expected to improve the performance of AI-MADRS. Our findings suggest that AI technologies can significantly modernize and potentially revolutionize the realm of depression assessments., (© 2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.)
- Published
- 2024
- Full Text
- View/download PDF
28. Association between copy number variations in parkin (PRKN) and schizophrenia and autism spectrum disorder: A case-control study.
- Author
-
Lo T, Kushima I, Kimura H, Aleksic B, Okada T, Kato H, Inada T, Nawa Y, Torii Y, Yamamoto M, Kimura R, Funabiki Y, Kosaka H, Numata S, Kasai K, Sasaki T, Yokoyama S, Munesue T, Hashimoto R, Yasuda Y, Fujimoto M, Usami M, Itokawa M, Arai M, Ohi K, Someya T, Watanabe Y, Egawa J, Takahashi T, Suzuki M, Yamasue H, Iwata N, Ikeda M, and Ozaki N
- Subjects
- Humans, Case-Control Studies, Comparative Genomic Hybridization, DNA Copy Number Variations, Genome-Wide Association Study, Ubiquitin-Protein Ligases genetics, Autism Spectrum Disorder genetics, Schizophrenia
- Abstract
Aim: The present study aimed to examine the association between copy number variations (CNVs) in parkin (PRKN) and schizophrenia (SCZ) and autism spectrum disorder (ASD) in a large case-control sample., Method: Array comparative genomic hybridization was performed on 3111 cases with SCZ, 1236 cases with ASD, and 2713 controls. We systematically prioritized likely pathogenic CNVs (LP-CNVs) in PRKN and examined their association with SCZ and ASD., Results: In total, 3014 SCZ cases (96.9%), 1205 ASD cases (97.5%), and 2671 controls (98.5%) passed quality control. We found that monoallelic carriers of LP-CNVs in PRKN were common (70/6890, 1.02%) and were not at higher risk of SCZ (p = 0.29) or ASD (p = 0.72). We observed that the distribution pattern of LP-CNVs in the Japanese population was consistent with those in other populations. We also identified a patient diagnosed with SCZ and early-onset Parkinson's disease carrying biallelic pathogenic CNVs in PRKN. The absence of Parkinson's symptoms in 10 other monoallelic carriers of the same pathogenic CNV further reflects the lack of effect of monoallelic pathogenic variants in PRKN in the absence of a second hit., Conclusion: The present findings suggest that monoallelic CNVs in PRKN do not confer a significant risk for SCZ or ASD. However, further studies to investigate the association between biallelic CNVs in PRKN and SCZ and ASD are warranted., (© 2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.)
- Published
- 2024
- Full Text
- View/download PDF
29. Indoleamine 2,3-dioxygenase 2 deficiency associates with autism-like behavior via dopaminergic neuronal dysfunction.
- Author
-
Ishikawa M, Yamamoto Y, Wulaer B, Kunisawa K, Fujigaki H, Ando T, Kimura H, Kushima I, Arioka Y, Torii Y, Mouri A, Ozaki N, Nabeshima T, and Saito K
- Subjects
- Animals, Humans, Mice, Dopamine, Dopaminergic Neurons, Indoleamine-Pyrrole 2,3,-Dioxygenase genetics, Autism Spectrum Disorder genetics, Autistic Disorder
- Abstract
Indoleamine 2,3-dioxygenase 2 (IDO2) is an enzyme of the tryptophan-kynurenine pathway that is constitutively expressed in the brain. To provide insight into the physiological role of IDO2 in the brain, behavioral and neurochemical analyses in IDO2 knockout (KO) mice were performed. IDO2 KO mice showed stereotyped behavior, restricted interest and social deficits, traits that are associated with behavioral endophenotypes of autism spectrum disorder (ASD). IDO2 was colocalized immunohistochemically with tyrosine-hydroxylase-positive cells in dopaminergic neurons. In the striatum and amygdala of IDO2 KO mice, decreased dopamine turnover was associated with increased α-synuclein level. Correspondingly, levels of downstream dopamine D1 receptor signaling molecules such as brain-derived neurotrophic factor and c-Fos positive proteins were decreased. Furthermore, decreased abundance of ramified-type microglia resulted in increased dendritic spine density in the striatum of IDO2 KO mice. Both chemogenetic activation of dopaminergic neurons and treatment with methylphenidate, a dopamine reuptake inhibitor, ameliorated the ASD-like behavior of IDO2 KO mice. Sequencing analysis of exon regions in IDO2 from 309 ASD samples identified a rare canonical splice site variant in one ASD case. These results suggest that the IDO2 gene is, at least in part, a factor closely related to the development of psychiatric disorders., (© 2023 Federation of European Biochemical Societies.)
- Published
- 2024
- Full Text
- View/download PDF
30. Distinct subdivisions of subcortical U-fiber regions in the gyrencephalic ferret brain.
- Author
-
Yoshino M, Shiraishi Y, Saito K, Kameya N, Hamabe-Horiike T, Shinmyo Y, Nakada M, Ozaki N, and Kawasaki H
- Subjects
- Animals, Humans, Ferrets physiology, Brain, Myelin Sheath, Axons, Cerebrum, White Matter
- Abstract
The human cerebrum contains a large amount of cortico-cortical association fibers. Among them, U-fibers are short-range association fibers located in white matter immediately deep to gray matter. Although U-fibers are thought to be crucial for higher cognitive functions, the organization within U-fiber regions are still unclear. Here we investigated the properties of U-fiber regions in the ferret cerebrum using neurochemical, neuronal tracing, immunohistochemical and electron microscopic techniques. We found that U-fiber regions can be subdivided into two regions, which we named outer and inner U-fiber regions. We further uncovered that outer U-fiber regions have smaller-diameter axons with thinner myelin compared with inner U-fiber regions. These findings may indicate functional complexity within U-fiber regions in the cerebrum., Competing Interests: Competing interests The authors declare no competing interests., (Copyright © 2023 Elsevier Ltd and Japan Neuroscience Society. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. Lithium response in bipolar disorder is associated with focal adhesion and PI3K-Akt networks: a multi-omics replication study.
- Author
-
Ou AH, Rosenthal SB, Adli M, Akiyama K, Akula N, Alda M, Amare AT, Ardau R, Arias B, Aubry JM, Backlund L, Bauer M, Baune BT, Bellivier F, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Cervantes P, Chen GB, Chen HC, Chillotti C, Cichon S, Clark SR, Colom F, Cousins DA, Cruceanu C, Czerski PM, Dantas CR, Dayer A, Del Zompo M, Degenhardt F, DePaulo JR, Étain B, Falkai P, Fellendorf FT, Ferensztajn-Rochowiak E, Forstner AJ, Frisén L, Frye MA, Fullerton JM, Gard S, Garnham JS, Goes FS, Grigoroiu-Serbanescu M, Grof P, Gruber O, Hashimoto R, Hauser J, Heilbronner U, Herms S, Hoffmann P, Hofmann A, Hou L, Jamain S, Jiménez E, Kahn JP, Kassem L, Kato T, Kittel-Schneider S, König B, Kuo PH, Kusumi I, Lackner N, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, Jaramillo CAL, MacQueen G, Maj M, Manchia M, Marie-Claire C, Martinsson L, Mattheisen M, McCarthy MJ, McElroy SL, McMahon FJ, Mitchell PB, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Nöthen MM, Novák T, Ösby U, Ozaki N, Papiol S, Perlis RH, Pisanu C, Potash JB, Pfennig A, Reich-Erkelenz D, Reif A, Reininghaus EZ, Rietschel M, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schubert KO, Schulze TG, Schweizer BW, Seemüller F, Severino G, Shekhtman T, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Squassina A, Stamm T, Stopkova P, Tighe SK, Tortorella A, Turecki G, Vieta E, Volkert J, Witt S, Wray NR, Wright A, Young LT, Zandi PP, and Kelsoe JR
- Subjects
- Humans, Proto-Oncogene Proteins c-akt genetics, Phosphatidylinositol 3-Kinases genetics, Genome-Wide Association Study, Multiomics, Focal Adhesions, Lithium pharmacology, Lithium therapeutic use, Bipolar Disorder drug therapy, Bipolar Disorder genetics
- Abstract
Lithium is the gold standard treatment for bipolar disorder (BD). However, its mechanism of action is incompletely understood, and prediction of treatment outcomes is limited. In our previous multi-omics study of the Pharmacogenomics of Bipolar Disorder (PGBD) sample combining transcriptomic and genomic data, we found that focal adhesion, the extracellular matrix (ECM), and PI3K-Akt signaling networks were associated with response to lithium. In this study, we replicated the results of our previous study using network propagation methods in a genome-wide association study of an independent sample of 2039 patients from the International Consortium on Lithium Genetics (ConLiGen) study. We identified functional enrichment in focal adhesion and PI3K-Akt pathways, but we did not find an association with the ECM pathway. Our results suggest that deficits in the neuronal growth cone and PI3K-Akt signaling, but not in ECM proteins, may influence response to lithium in BD., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
32. Effect of single-administration of D-sorbitol pretreatment on the bitterness and continued willingness to take asenapine: a randomized, single-blind, placebo-controlled, crossover trial.
- Author
-
Wada S, Iwamoto K, Okumura H, Hida H, Hiraoka S, Kamei A, Mori D, Yamada K, Ando M, Ozaki N, and Ikeda M
- Subjects
- Adult, Humans, Taste, Single-Blind Method, Cross-Over Studies, Heterocyclic Compounds, 4 or More Rings pharmacology, Heterocyclic Compounds, 4 or More Rings therapeutic use, Treatment Outcome, Antipsychotic Agents adverse effects, Dibenzocycloheptenes
- Abstract
Background: Asenapine has unique orally-related side effects, such as a bitter taste induced by sublingual administration, which often results in discontinuation of the medication. While the FDA has approved black-cherry-flavored asenapine, several countries have prescribed only unflavored versions. Specifically, Asians commonly report experiencing the bitterness of asenapine because they are more sensitive to bitter tastes than other ethnic groups. In this study, with the aim of improving adherence by reducing the bitterness of asenapine, we investigated the effects of D-sorbitol, which reduced the bitterness parameters of taste sensors in our previous basic study on the bitterness and continuity of asenapine among patients with schizophrenia., Methods: Twenty adult patients with schizophrenia were included in this single-blind, placebo-controlled, crossover trial. Participants rinsed their mouths with single-administration of D-sorbitol or a placebo prior to each administration of asenapine. We then conducted the questionnaires and assessed changes in the bitterness of asenapine (primary end point) and willingness to continue its use (secondary end point)., Results: D-sorbitol significantly improved the bitterness of asenapine (p = 0.038). Although it did not significantly increase the willingness to continue asenapine (p = 0.180), it did show improvement over the placebo in enhancing willingness to continue, especially in patients who were not accustomed to its taste., Conclusion: Our findings indicate that single-administration of D-sorbitol significantly reduces the bitterness of asenapine. In countries where flavored asenapine is not available, this finding could benefit patients who were not accustomed to its bitter taste., Trial Registration: This study was registered in the Japan Registry of Clinical Trials (jRCTs041210019) on May 14, 2021., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
33. Combined Experiments with in Vivo Fiber Photometry and Behavior Tests Can Facilitate the Measurement of Neuronal Activity in the Primary Somatosensory Cortex and Hyperalgesia in an Inflammatory Pain Mice Model.
- Author
-
Ishikawa T, Uta D, Okuda H, Potapenko I, Hori K, Kume T, and Ozaki N
- Subjects
- Animals, Mice, Behavior Rating Scale, Calcium, Somatosensory Cortex, Calcium, Dietary, Disease Models, Animal, Neurons, Photometry, Hyperalgesia, Chronic Pain
- Abstract
The pain matrix, which includes several brain regions that respond to pain sensation, contribute to the development of chronic pain. Thus, it is essential to understand the mechanism of causing chronic pain in the pain matrix such as anterior cingulate (ACC), or primary somatosensory (S1) cortex. Recently, combined experiment with the behavior tests and in vivo calcium imaging using fiber photometry revealed the interaction between the neuronal function in deep brain regions of the pain matrix including ACC and the phenotype of chronic pain. However, it remains unclear whether this combined experiment can identify the interaction between neuronal activity in S1, which receive pain sensation, and pain behaviors such as hyperalgesia or allodynia. In this study, to examine whether the interaction between change of neuronal activity in S1 and hyperalgesia in hind paw before and after causing inflammatory pain was detected from same animal, the combined experiment of in vivo fiber photometry system and von Frey hairs test was applied. This combined experiment detected that amplitude of calcium responses in S1 neurons increased and the mechanical threshold of hind paw decreased from same animals which have an inflammatory pain. Moreover, we found that the values between amplitude of calcium responses and mechanical thresholds were shifted to negative correlation after causing inflammatory pain. Thus, the combined experiment with fiber photometry and the behavior tests has a possibility that can simultaneously consider the interaction between neuronal activity in pain matrix and pain induced behaviors and the effects of analgesics or pain treatments.
- Published
- 2024
- Full Text
- View/download PDF
34. The Comet Interceptor Mission.
- Author
-
Jones GH, Snodgrass C, Tubiana C, Küppers M, Kawakita H, Lara LM, Agarwal J, André N, Attree N, Auster U, Bagnulo S, Bannister M, Beth A, Bowles N, Coates A, Colangeli L, Corral van Damme C, Da Deppo V, De Keyser J, Della Corte V, Edberg N, El-Maarry MR, Faggi S, Fulle M, Funase R, Galand M, Goetz C, Groussin O, Guilbert-Lepoutre A, Henri P, Kasahara S, Kereszturi A, Kidger M, Knight M, Kokotanekova R, Kolmasova I, Kossacki K, Kührt E, Kwon Y, La Forgia F, Levasseur-Regourd AC, Lippi M, Longobardo A, Marschall R, Morawski M, Muñoz O, Näsilä A, Nilsson H, Opitom C, Pajusalu M, Pommerol A, Prech L, Rando N, Ratti F, Rothkaehl H, Rotundi A, Rubin M, Sakatani N, Sánchez JP, Simon Wedlund C, Stankov A, Thomas N, Toth I, Villanueva G, Vincent JB, Volwerk M, Wurz P, Wielders A, Yoshioka K, Aleksiejuk K, Alvarez F, Amoros C, Aslam S, Atamaniuk B, Baran J, Barciński T, Beck T, Behnke T, Berglund M, Bertini I, Bieda M, Binczyk P, Busch MD, Cacovean A, Capria MT, Carr C, Castro Marín JM, Ceriotti M, Chioetto P, Chuchra-Konrad A, Cocola L, Colin F, Crews C, Cripps V, Cupido E, Dassatti A, Davidsson BJR, De Roche T, Deca J, Del Togno S, Dhooghe F, Donaldson Hanna K, Eriksson A, Fedorov A, Fernández-Valenzuela E, Ferretti S, Floriot J, Frassetto F, Fredriksson J, Garnier P, Gaweł D, Génot V, Gerber T, Glassmeier KH, Granvik M, Grison B, Gunell H, Hachemi T, Hagen C, Hajra R, Harada Y, Hasiba J, Haslebacher N, Herranz De La Revilla ML, Hestroffer D, Hewagama T, Holt C, Hviid S, Iakubivskyi I, Inno L, Irwin P, Ivanovski S, Jansky J, Jernej I, Jeszenszky H, Jimenéz J, Jorda L, Kama M, Kameda S, Kelley MSP, Klepacki K, Kohout T, Kojima H, Kowalski T, Kuwabara M, Ladno M, Laky G, Lammer H, Lan R, Lavraud B, Lazzarin M, Le Duff O, Lee QM, Lesniak C, Lewis Z, Lin ZY, Lister T, Lowry S, Magnes W, Markkanen J, Martinez Navajas I, Martins Z, Matsuoka A, Matyjasiak B, Mazelle C, Mazzotta Epifani E, Meier M, Michaelis H, Micheli M, Migliorini A, Millet AL, Moreno F, Mottola S, Moutounaick B, Muinonen K, Müller DR, Murakami G, Murata N, Myszka K, Nakajima S, Nemeth Z, Nikolajev A, Nordera S, Ohlsson D, Olesk A, Ottacher H, Ozaki N, Oziol C, Patel M, Savio Paul A, Penttilä A, Pernechele C, Peterson J, Petraglio E, Piccirillo AM, Plaschke F, Polak S, Postberg F, Proosa H, Protopapa S, Puccio W, Ranvier S, Raymond S, Richter I, Rieder M, Rigamonti R, Ruiz Rodriguez I, Santolik O, Sasaki T, Schrödter R, Shirley K, Slavinskis A, Sodor B, Soucek J, Stephenson P, Stöckli L, Szewczyk P, Troznai G, Uhlir L, Usami N, Valavanoglou A, Vaverka J, Wang W, Wang XD, Wattieaux G, Wieser M, Wolf S, Yano H, Yoshikawa I, Zakharov V, Zawistowski T, Zuppella P, Rinaldi G, and Ji H
- Abstract
Here we describe the novel, multi-point Comet Interceptor mission. It is dedicated to the exploration of a little-processed long-period comet, possibly entering the inner Solar System for the first time, or to encounter an interstellar object originating at another star. The objectives of the mission are to address the following questions: What are the surface composition, shape, morphology, and structure of the target object? What is the composition of the gas and dust in the coma, its connection to the nucleus, and the nature of its interaction with the solar wind? The mission was proposed to the European Space Agency in 2018, and formally adopted by the agency in June 2022, for launch in 2029 together with the Ariel mission. Comet Interceptor will take advantage of the opportunity presented by ESA's F-Class call for fast, flexible, low-cost missions to which it was proposed. The call required a launch to a halo orbit around the Sun-Earth L2 point. The mission can take advantage of this placement to wait for the discovery of a suitable comet reachable with its minimum Δ V capability of 600 ms - 1 . Comet Interceptor will be unique in encountering and studying, at a nominal closest approach distance of 1000 km, a comet that represents a near-pristine sample of material from the formation of the Solar System. It will also add a capability that no previous cometary mission has had, which is to deploy two sub-probes - B1, provided by the Japanese space agency, JAXA, and B2 - that will follow different trajectories through the coma. While the main probe passes at a nominal 1000 km distance, probes B1 and B2 will follow different chords through the coma at distances of 850 km and 400 km, respectively. The result will be unique, simultaneous, spatially resolved information of the 3-dimensional properties of the target comet and its interaction with the space environment. We present the mission's science background leading to these objectives, as well as an overview of the scientific instruments, mission design, and schedule., Competing Interests: Competing InterestsThe authors declare no competing interests., (© The Author(s) 2024.)
- Published
- 2024
- Full Text
- View/download PDF
35. Neuropathological substrate of incident dementia in older patients with schizophrenia: A clinicopathological study.
- Author
-
Arafuka S, Fujishiro H, Torii Y, Sekiguchi H, Habuchi C, Miwa A, Yoshida M, Iritani S, Iwasaki Y, Ikeda M, and Ozaki N
- Subjects
- Humans, Aged, Brain pathology, Comorbidity, Neurodegenerative Diseases complications, Schizophrenia complications, Alzheimer Disease diagnosis
- Abstract
Aim: Clinical studies reported that patients with schizophrenia are at a higher risk of developing dementia than people without schizophrenia. However, early neuropathological studies have shown that the incidence of Alzheimer's disease (AD) in schizophrenia patients does not differ from that in controls. These inconsistent results may be attributable to the inclusion of non-AD dementia, but there have been few clinicopathological studies in older patients with schizophrenia based on the current neuropathological classification. This study aimed to investigate the neuropathological basis of incident dementia in older patients with schizophrenia., Methods: We systematically examined 32 brains of old patients with schizophrenia using standardized pathological methods. The severity of dementia-related neuropathologies was analyzed using standardized semiquantitative assessments. After excluding patients who fulfilled the neuropathological criteria, clinicopathological variables were compared between patients with and without incident dementia to identify potential differences., Results: Seven patients fulfilled the pathological criteria for AD (n = 3), argyrophilic grain disease (AGD) (n = 2), dementia with Lewy bodies (n = 1), and AGD/progressive supranuclear palsy (n = 1). Among 25 patients for whom a neuropathological diagnosis was not obtained, 10 had dementia, but the clinicopathological findings did not differ from the remaining 15 patients without dementia., Conclusion: Two types of older schizophrenia patient present dementia: patients with co-existing neurodegenerative disease and patients who do not meet pathological criteria based on the current classification. To understand the neurobiological aspects of incident dementia in older patients with schizophrenia, further clinicopathological studies are needed that do not simply analyze incident dementia as a comorbidity of conventional dementia-related neuropathologies., (© 2023 The Authors. Psychiatry and Clinical Neurosciences © 2023 Japanese Society of Psychiatry and Neurology.)
- Published
- 2024
- Full Text
- View/download PDF
36. [The role of bioactive lipid mediators in nasal congestion of allergic rhinitis].
- Author
-
Ozaki N, Sakamoto N, and Murata T
- Subjects
- Humans, Animals, Nasal Obstruction metabolism, Lipids, Rhinitis, Allergic metabolism
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.